Kisspeptin-10 Dosage: Doses Studied, Units and Chart
What doses of Kisspeptin-10 have been used in published research, how they convert to syringe units, and what is still unknown.
- Doses studied
- 11 studies
- with a stated dose, listed below
- Frequency
- Varies by study
- as used in studies
- Half-life
- mean elimination half-life 1.3-2.2 hours
- subcutaneous (analog MVT-602), in people · Fertility and sterility 2024, PMID 37925096
- Vial sizes sold
- 5 mg, 10 mg
Doses used in published studies
Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.
| Dose | Frequency and route | Study type | Source |
|---|---|---|---|
| 1.25-10.0 nmol/kg/h acute; 150 nmol/h daily 8 h for 12 days | daily 8 h on, 16 h off · subcutaneous infusion (kisspeptin-10) · 12 days | Human RCTn = 15 | European journal of endocrinology 2026, PMID 42549827 |
| 0.1 to 3.0 ug MVT-602 | single dose · subcutaneous | Human RCT | Fertility and sterility 2024, PMID 37925096 |
| 1 nmol/kg/h kisspeptin-54 | intravenous infusion · 75 minutes | Human RCTn = 40 | JAMA network open 2022, PMID 36287566 |
| 6.4 nmol/kg (kisspeptin-54) | twice daily · subcutaneous · 7 days | Human controlled trialn = 5 | Clinical endocrinology 2014, PMID 24863252 |
| iv bolus 0.01-3.0 ug/kg; infusion 1.5-4 ug/kg/h | intravenous (kisspeptin-10) · infusion up to 22.5 h | Human controlled trial | The Journal of clinical endocrinology and metabolism 2011, PMID 21632807 |
| 6.4 nmol/kg (kisspeptin-54) | twice daily · subcutaneous · 2 weeks | Human RCT | The Journal of clinical endocrinology and metabolism 2009, PMID 19820030 |
| 0.2-6.4 nmol/kg (kisspeptin-54) | subcutaneous bolus | Human controlled trial | The Journal of clinical endocrinology and metabolism 2007, PMID 17635940 |
| 6.4-12.8 nmol/kg of kisspeptin-54 | twice daily · subcutaneous · 21 days | Human uncontrolled trialn = 12 | Human reproduction 2019, PMID 31820802 |
| 1.6 to 12.8 nmol/kg (kisspeptin-54) | single injection · subcutaneous | Human uncontrolled trialn = 53 | The Journal of clinical investigation 2014, PMID 25036713 |
| 0.3-10 nmol/injection site of kisspeptin-10 | intradermal | Animal · mouse (CD1) (not a human result) | PloS one 2011, PMID 21347414 |
| 20 nmol/rat/day kisspeptin-10 | 7 days | Animal · rat (not a human result)n = 24 | Cell biochemistry and function 2010, PMID 20517893 |
Dose to syringe units
For a 10 mg vial mixed with 2 mL of bacteriostatic water (5 mg/mL), on a U-100 syringe. These are reference amounts for the math, not suggested doses.
- 100 mcg
- 2 u
- 250 mcg
- 5 u
- 500 mcg
- 10 u
- 750 mcg
- 15 u
- 1000 mcg
- 20 u
Before anyone considers it
- Kisspeptin-10 is not FDA approved for any use.
- Products sold as research chemicals are not checked by the FDA for identity, purity or dose.
- Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
- People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.
Infusion schedules in healthy men
Acute subcutaneous kisspeptin-10 infusions of 1.25-10.0 nmol/kg/h were compared, then continuous 180 nmol/h for 5 days, then daily 8 h infusions at 150 nmol/h for 12 days.[3]
After 5 days of continuous kisspeptin-10, gonadotropin concentrations were similar to vehicle, while daily 8 h infusions over 12 days sustained increases in gonadotropins.[3]
Frequency changed the response in women
In women with hypothalamic amenorrhea given kisspeptin-54 at 6.4 nmol/kg twice daily for 2 wk, LH and FSH rose sharply on the first injection day and the responses were significantly reduced by the 14th.[8]
Twice-weekly kisspeptin-54 produced only partial desensitization, versus complete tolerance with twice-daily dosing, and raised hormones after 8 weeks.[14]
In an IVF study, 53 women received a single subcutaneous kisspeptin-54 injection at 1.6, 3.2, 6.4 or 12.8 nmol/kg after superovulation.[10]
Regulatory
Drugs@FDA lists no kisspeptin product, so the nmol/kg figures above have no labelled counterpart.[15]
Common questions
How many units is 500 mcg of Kisspeptin-10?
It depends on the water added. A 10 mg vial with 2 mL of water gives 5 mg/mL, so 500 mcg is 10 units on a U-100 syringe. Use the calculator for other mixes.
Is Kisspeptin-10 FDA approved?
No. Kisspeptin-10 is not FDA approved for any use.
What is the kisspeptin dosing in studies?
In healthy men, kisspeptin-10 was infused at 150 nmol/h for 8 h daily over 12 days; the kisspeptin-54 studies in women used nmol/kg injections.[3]
Is there a kisspeptin dosage for women?
The women's studies used kisspeptin-54, for example 6.4 nmol/kg twice daily for 2 wk, after which responses were significantly reduced by the 14th injection day.[8]
Is there a kisspeptin 10 dosage for men?
In healthy men, kisspeptin-10 was given as 1.25-10.0 nmol/kg/h acute infusions and as fixed nmol/h infusions over several days.[3]
More on Kisspeptin-10
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men.European journal of endocrinology · 2026PMID 42549827Accessed 2 Oct 2026
- 4Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals.Fertility and sterility · 2024PMID 37925096Accessed 2 Oct 2026
- 5Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial.JAMA network open · 2022PMID 36287566Accessed 2 Oct 2026
- 6Acute and chronic effects of kisspeptin-54 administration on GH, prolactin and TSH secretion in healthy women.Clinical endocrinology · 2014PMID 24863252Accessed 2 Oct 2026
- 7Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.The Journal of clinical endocrinology and metabolism · 2011PMID 21632807Accessed 2 Oct 2026
- 8Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis.The Journal of clinical endocrinology and metabolism · 2009PMID 19820030Accessed 2 Oct 2026
- 9Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women.The Journal of clinical endocrinology and metabolism · 2007PMID 17635940Accessed 2 Oct 2026
- 10Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.The Journal of clinical investigation · 2014PMID 25036713Accessed 2 Oct 2026
- 11Direct and indirect effects of kisspeptin on liver oxidant and antioxidant systems in young male rats.Cell biochemistry and function · 2010PMID 20517893Accessed 2 Oct 2026
- 12Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome.Human reproduction (Oxford, England) · 2019PMID 31820802Accessed 11 Oct 2026
- 13The vasoactive potential of kisspeptin-10 in the peripheral vasculature.PloS one · 2011PMID 21347414Accessed 11 Oct 2026
- 14Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea.Clinical pharmacology and therapeutics · 2010PMID 20980998Accessed 2 Oct 2026
- 15Drugs@FDA (openFDA) search: active ingredient "kisspeptin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.